Shenzhen Tagrisso Biopharmaceutical

Shenzhen Tagrisso Biopharmaceutical is a Chinese biotechnology company focused on the development of oncology therapeutics, particularly targeting lung cancer. The company appears to focus on the research and development of small molecule inhibitors that target specific genetic mutations, such as those in the Epidermal Growth Factor Receptor (EGFR). While the company shares a name with AstraZeneca's blockbuster drug Tagrisso (osimertinib), it operates as an independent entity within the Shenzhen biopharmaceutical cluster. Its activities primarily involve early-stage drug discovery and optimization of kinase inhibitors for the treatment of solid tumors.